Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 5, 2025

APC anti-human CD274 (B7-H1, PD-L1)

RRID:AB_940360
Type: Antibody

Proper Citation

(BioLegend Cat# 329708, RRID:AB_940360)

Antibody Information

URL: http://antibodyregistry.org/AB_940360

Proper Citation: (BioLegend Cat# 329708, RRID:AB_940360)

Target Antigen: CD274

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-human CD274 (B7-H1, PD-L1)

Description: This monoclonal targets CD274

Target Organism: human

Clone ID: Clone 29E.2A3

Antibody ID: AB_940360

Vendor: BioLegend

Catalog Number: 329708

Alternative Catalog Numbers: 329707

Record Creation Time: 20231110T042440+0000

Record Last Update: 20241115T044114+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-human CD274 (B7-H1, PD-L1).

No alerts have been found for APC anti-human CD274 (B7-H1, PD-L1).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Zheng C, et al. (2024) IFN?-induced BST2+ tumor-associated macrophages facilitate immunosuppression and tumor growth in pancreatic cancer by ERK-CXCL7 signaling. Cell reports, 43(4), 114088.

McGee AV, et al. (2024) Modular vector assembly enables rapid assessment of emerging CRISPR technologies. Cell genomics, 4(3), 100519.

Wang M, et al. (2024) Therapeutic induction of ferroptosis in tumors using PD-L1 targeting antibody nanogel conjugates. Cell chemical biology, 31(12), 2039.

Wang H, et al. (2024) Nucleo-cytosolic acetyl-CoA drives tumor immune evasion by regulating PD-L1 in melanoma. Cell reports, 43(12), 115015.

Wang Q, et al. (2024) Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3. Cell reports. Medicine, 5(2), 101357.

Russo S, et al. (2024) Low-dose decitabine enhances the efficacy of viral cancer vaccines for immunotherapy. Molecular therapy. Oncology, 32(1), 200766.

Felices M, et al. (2023) Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer. Cancer immunology research, 11(5), 674.

Rudjord-Levann AM, et al. (2023) Galectin-1 induces a tumor-associated macrophage phenotype and upregulates indoleamine 2,3-dioxygenase-1. iScience, 26(7), 106984.

Griffith AL, et al. (2023) Optimization of Cas12a for multiplexed genome-scale transcriptional activation. Cell genomics, 3(9), 100387.

Pinto C, et al. (2023) Tumor microenvironment mimicking 3D models unveil the multifaceted

effects of SMAC mimetics. iScience, 26(4), 106381.

Yang Z, et al. (2022) Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance. Cancer discovery, 12(8), 1942.

Taniguchi H, et al. (2022) WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell reports, 39(7), 110814.

Pan R, et al. (2022) Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell, 185(9), 1521.

Leite NC, et al. (2020) Modeling Type 1 Diabetes In Vitro Using Human Pluripotent Stem Cells. Cell reports, 32(2), 107894.

Renner K, et al. (2019) Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy. Cell reports, 29(1), 135.

Wallstabe L, et al. (2019) ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI insight, 4(18).

Su S, et al. (2018) Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages. Cell, 175(2), 442.